Document Detail


Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
MedLine Citation:
PMID:  9236426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although retrospective analyses have revealed an association between survival and coronary angiography and angioplasty in patients with acute myocardial infarction complicated by cardiogenic shock, the degree to which bias in the selection of patients to undergo these procedures contributes to this observation remains unclear. METHODS AND RESULTS: We studied 2200 patients in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial with acute myocardial infarction complicated by cardiogenic shock (systolic blood pressure < 90 mm Hg for > or = 1 hour) who survived > or = 1 hour after the onset of shock to determine the influence of an aggressive strategy of early angiography (within 24 hours of shock onset) and coronary angioplasty or bypass surgery, if appropriate, on survival. Revascularization was not protocol mandated but was selected by the attending physicians. Shock was present on admission in 11% and developed after admission in 89% of shock patients. The 30-day mortality was 38% in the 406 patients who underwent early angiography and were referred within 24 hours for angioplasty (n = 175), bypass surgery (n = 36), angioplasty and bypass surgery (n = 22), or neither (late or no revascularization, n = 173) compared with 62% in the 1794 patients who did not (P = .0001). However, there were important differences in the baseline characteristics of the two groups, including younger age (63 versus 68 years, P = .0001), less prior infarction (19% versus 27%, P = .001), and a shorter time to thrombolytic therapy (2.9 versus 3.2 hours, P = .0001) in patients treated with an aggressive strategy. Using multivariate logistic regression analysis to adjust for differences in baseline characteristics, an aggressive strategy was independently associated with reduced 30-day mortality (odds ratio, 0.43 [confidence interval, 0.34 to 0.54], P = .0001). CONCLUSIONS: An aggressive strategy of early angiography (and revascularization when appropriate) is associated with a reduction in mortality in patients with acute myocardial infarction and cardiogenic shock who receive thrombolytic therapy.
Authors:
P B Berger; D R Holmes; A L Stebbins; E R Bates; R M Califf; E J Topol
Related Documents :
15227186 - Coronary angioplasty in emergency treatment of myocardial infarction in a community-hos...
18762686 - The role of extracorporeal membrane oxygenation in emergent percutaneous coronary inter...
9477356 - Shock wave lithotripsy of urinary calculi with lithocut c-3000 in a small center.
9104986 - Intraaortic balloon pumping for cardiac support: trends in practice and outcome, 1968 t...
12909476 - Aortic regurgitation in the heterotopic rat heart transplant: effect on ventricular rem...
23830566 - Aids-related primary cardiac lymphoma with right-sided heart failure and high-grade av ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Circulation     Volume:  96     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-08-14     Completed Date:  1997-08-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  122-7     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA. berger.peter@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coronary Angiography
Female
Heart Catheterization
Heparin / therapeutic use
Humans
Injections, Intravenous
Injections, Subcutaneous
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction / mortality,  radiography,  therapy*
Myocardial Revascularization / methods*
Prospective Studies
Recurrence
Shock, Cardiogenic / mortality*,  therapy
Streptokinase / therapeutic use*
Survival Rate
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
9005-49-6/Heparin; EC 3.4.-/Streptokinase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarct...
Next Document:  Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and cl...